Navigation Links
QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
Date:5/10/2010

BEDMINSTER, N.J. and SYDNEY, May 10 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

"The successful outcome of this trial reinforces QRxPharma's intellectual property that defines MoxDuo CR as a novel, controlled-release formulation for sustained pain relief. We are now one step closer to addressing the needs of chronic pain patients and entering the multi-billion dollar chronic pain market," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "QRxPharma remains on track to finalising the MoxDuo CR tablet by the end of this year and to be in a position to initiate Phase 2 trials shortly thereafter."

The Phase 1 trial, a single dose crossover design, was conducted in 14 normal healthy volunteers at one U.S. clinical research site. This study compared the rate at which key components of the CR formulation were absorbed, distributed, metabolised and eliminated by the body to the pharmacokinetic profile of Oxycontin® 20 mg (sustained release oxycodone).

Pharmacokinetic results are encouraging, and the profile is consistent with expectations for a twice-daily formulation. Data from this study will significantly aid QRxPharma and its manufacturing partner, Patheon Inc., in finalising the target release profile for the product and finalising the composition of prototype MoxDuo CR tablets.

The Company's MoxDuo® product portfolio includes both immediate and controlled release, as well as intravenous formulations. "Our goal is to provide physicians and patients with a variety of complementary Dual-Opioids for managing moderate to severe pain from hospital to home," added Holaday.


'/>"/>
SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. ... announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as ... beginning April 10. Dr. Bell comes to Liberty from the Ohio University Heritage ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved ... Highway 121, Suite 210, McKinney, Texas 75070. It is in the heart of ... practice has grown, the need for more space has been paramount. This beautiful ...
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
Breaking Medicine News(10 mins):